TLRY · Tilray Brands, Inc. · Stock research

Current Thesis

The rescheduling story delivered its most concrete instalment on 2026-04-28, when the Federal Register carried the DEA final order moving FDA-approved cannabis drug products and state-licensed medical marijuana from Schedule I to Schedule III — and the stock made new lows afterward. The remaining leg, broad adult-use downscheduling, had its expedited hearing close on 2026-07-15 with a briefing calendar and nothing else: post-hearing briefs to Chief ALJ Derek Julius are due 2026-08-17, the recommendation carries no announced date, the Administrator holds the final pen, and the losing side can litigate. What moved the tape instead was operating: Q4 FY2026 on 2026-07-28 printed net revenue of $281.7M, +25.5% YoY, with beverage at $105.6M (+61%) overtaking cannabis as the largest segment, and FY2027 guidance of more than $1B revenue with $68–75M of adjusted EBITDA. a bounce that has taken RSI(14) to 68.7 without touching the 200-day, which sits roughly 25% higher.

Bullish and bearish views on Tilray Brands, Inc.

The model's bull view on Tilray Brands, Inc. (TLRY), in brief: Q4 FY2026, reported 2026-07-28: net revenue $281.7M, +25.5% YoY, against a consensus near $245.6M cited by Quiver Quantitative; Q4 adjusted EBITDA $31.9M, +16% YoY; gross margin 32%. The bear view: Partial rescheduling was granted in April 2026 and the shares are at $4.67 versus a 52-week high of $21.00, -77.8%. Both cases follow in full.

Bull Case

• Q4 FY2026, reported 2026-07-28: net revenue $281.7M, +25.5% YoY, against a consensus near $245.6M cited by Quiver Quantitative; Q4 adjusted EBITDA $31.9M, +16% YoY; gross margin 32%.
• Beverage revenue $105.6M in Q4, +61% YoY, now the largest segment. Management said on the 2026-07-28 call that BrewDog created a pro forma global beverage platform approaching $500M in annual revenue and that BrewDog is stabilised.
• FY2027 guidance given 2026-07-28: revenue above $1B, adjusted EBITDA $68–75M versus $61.1M in FY2026, with international expected around $700M (~60% of the total). Project 420 was credited with $33M of annualized savings.
• Balance sheet: approximately $235M of cash, restricted cash and marketable securities at FY2026 year-end, against a market capitalisation of roughly $497.5M quoted at the 2026-07-28 print — close to half the equity value in liquid assets.
• Reform optionality has not expired, it has lost its date. Trump's executive order of 2025-12-18 directed the Attorney General to move marijuana to Schedule III expeditiously; the 2026-04-28 final order executed the partial move; the record on the broader question closes 2026-08-17.
• International medical cannabis is the one leg growing on its own economics: Q3 FY2026 international cannabis revenue $24.12M, +73% YoY, on German volumes, with distribution at $82.96M (+35%).
• The hemp cleanup lands ~2026-11-12 under the Continuing Appropriations Act signed 2025-11-12, with the U.S. Hemp Roundtable estimating ~95% of hemp-cannabinoid products swept out of the gray market.

Bear Case

• Partial rescheduling was granted in April 2026 and the shares are at $4.67 versus a 52-week high of $21.00, -77.8%. A narrative that gets what it asked for and prints lows anyway has stopped setting the price.
• FY2026 adjusted EBITDA of $61.1M came in beneath the $62–72M band management reaffirmed at the Q3 print. The FY2027 guide is therefore built off a number that itself undershot.
• Quiver Quantitative reported diluted GAAP EPS of -$0.43 for Q4 alongside the revenue beat; the distance between that and $31.9M of adjusted EBITDA is where the non-cash charges sit.
• Share issuance is continuous and unannounced in advance: 2,638,341 shares for $12M principal of the 5.20% converts due 2027-06-15 between 2026-06-15 and 2026-06-24 (8-K filed 2026-06-30), then 1,377,334 shares for a further $6M on 2026-08-04
• The growth engine dilutes mix margin: full-year beverage gross margin fell to 36% from 39%.
• TD Cowen cut its target to $5 from $7 on 2026-07-14 while maintaining Buy — a target reset below where the shares now trade on the sell-side's own most recent dated action.
• Cannabis is a minority of consolidated revenue. Whatever the ALJ recommends, TLRY captures less of it per dollar of revenue than pure US-exposed operators.
• Trade-press reads of the process (Recovered.org, Cannabis Legalization News) place the ALJ recommendation in late 2026 or early 2027. Nothing on the calendar forces it.

Setup & Price Structure

• Reference close 2026-08-14: $4.67. Three-month return -12.2% even after the August advance. Distance from the 52-week high of $21.00: -77.8%.
• The prior floor did not hold. The 2026-07-08 low of $4.20 was broken before the print — 24/7 Wall St quoted $4.03 on 2026-07-28, with the stock down 55% year-to-date at that moment. The reclaim of $4.20 happened after the results, which dates the current leg to earnings rather than to policy.
• RSI(14) at 68.7 is the strongest momentum reading of the recent range, and it has been achieved entirely below the 200-day. Reclaiming that average requires roughly $5.80–6.00 on a daily close; between $4.67 and there the chart offers no prior shelf.
• Positioning observables, stated as observables: retail-facing coverage clustered in the first half of August (an unusual-options "whale activity" screen on 2026-08-03, "should you chase the rally" framing on the Trump-rescheduling angle); the company sold equity into that strength on 2026-08-04; no earnings date falls inside the next 30 days, since fiscal Q1 does not close until 2026-08-31.
• The narrative is dead for the rescheduling leg. What dates it is the sequence — 2026-04-28 final order delivered, 2026-07-08 new low, 2026-07-15 hearing closed with no timeline, sub-$4.20 trade in late July. The label would flip back to live on a weekly close above $6.00 that puts the 200-day underneath on an ALJ-recommendation headline. Separately, the beverage-and-international business is a different story at an earlier stage, and at ~0.5x FY2027 guided revenue the tape is not paying for it yet.

Catalyst Calendar (next 30 days)

• 2026-08-31 — Fiscal Q1 FY2027 quarter end. No release on the date; fiscal year ends 31 May.
• ~2026-10-08 (est.) — Q1 FY2027 results, outside the 30-day window. First measurement against the >$1B revenue and $68–75M adjusted EBITDA guide.
• ~2026-11-12 (est.) — Hemp-derived THC recriminalization effective date under the Continuing Appropriations Act. Outside the window, flagged because a deferral to 2028 removes the licensed-product tailwind.

Elapsed catalysts

• 2026-08-17 — Post-hearing briefs due to Chief ALJ Derek Julius, 50-page cap. Closes the evidentiary record on broad Schedule III. No decision attaches to the date, and no recommendation date is announced with it. (passed 9d ago)
• Undated, any time after 2026-08-17 — ALJ recommendation to the DEA Administrator. Not scheduled; trade-press estimates cluster in late 2026/early 2027. (passed 9d ago)

What Would Change Our Mind

The structural condition that would re-rate the read is the 200-day, not the news flow: a daily close above $5.80 that holds for a full week would mark the first reclaim of that average since the breakdown and would make the August bounce something other than a post-earnings drift. Absent that, a daily close below $4.20 gives back the entire post-print reclaim and re-confirms the July downtrend, and the pre-print $4.03 area quoted on 2026-07-28 becomes the next reference. On the policy side, 2026-08-17 passing with briefs filed and no announced recommendation date leaves the reform leg formally undated into October results — a catalyst spent without producing one. On fundamentals, an FY2027 adjusted EBITDA guide taken below $68M at the October print, or beverage revenue growth decelerating from the +61% Q4 rate toward the low twenties, removes the operating leg that carried the stock off $4.03. In the other direction, a published Federal Register order covering adult-use with an effective date would restore a dated event to a name that currently has none.

Correlation Notes

• Policy beta first: the name moves on DEA/DOJ/White House statements across the cannabis complex, and the 2026-08 advance was attributed in coverage to renewed Trump-driven Schedule III expectations rather than to a company release.
• Segment beta is drifting toward alcohol/beverage demand as beverage becomes the largest line ($105.6M in Q4), which decouples part of the revenue base from US cannabis policy while adding consumer-staples sensitivity.
• The German and wider international medical business (+73% YoY in Q3 FY2026) tracks EU regulatory volume and FX, independent of the DEA process.
• Roughly $235M of liquid assets against a ~$497.5M market capitalisation gives the equity a balance-sheet anchor, offset by the 5.20% converts due 2027-06-15 that are being retired in stock.
• As a sub-$5 name with heavy retail participation, it co-moves with speculative small-cap risk appetite on sessions with no policy headline.